Latest News

Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies
Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies

July 14th 2025

Takeda reveals promising phase 3 results for oveporexton, a potential breakthrough treatment for narcolepsy type 1, targeting excessive daytime sleepiness.

Alon Ben-Noon, MBA  (Credit: NeuroSense Therapeutics)
Late-Breaking Phase 2b PARADIGM Data Support Continued Development of PrimeC in ALS

July 14th 2025

This Week on NeurologyLive® — July 14, 2025
This Week on NeurologyLive® — July 14, 2025

July 14th 2025

Soluble TNF Inhibitor XPro Shows Mixed Results in Phase 2 MINDFuL Trial of Alzheimer Disease
Soluble TNF Inhibitor XPro Shows Mixed Results in Phase 2 MINDFuL Trial of Alzheimer Disease

July 13th 2025

NeurologyLive® Brain Games: July 13, 2025
NeurologyLive® Brain Games: July 13, 2025

July 13th 2025

Coverage of SLEEP 2025

Get direct access to interviews with experts, straight from the conference floor in Seattle, as well as the latest data and clinical news updates.

SLEEP 2025

Conference Coverage

View All
Exploring Tools to Target the Glymphatic System and Alzheimer Disease Risk: Andrew Varga, MD
Exploring Tools to Target the Glymphatic System and Alzheimer Disease Risk: Andrew Varga, MD

July 14th 2025

Alon Ben-Noon, MBA  (Credit: NeuroSense Therapeutics)
Late-Breaking Phase 2b PARADIGM Data Support Continued Development of PrimeC in ALS

July 14th 2025

María L. De León, MD
Centering Empathy in Parkinson Care by Listening Beyond the Diagnosis: María L. De León, MD

July 14th 2025

Elizabeth Seng, PhD
Using Veterans Health Data to Gain Insights on Sex Differences in Migraine and Stroke Risk: Elizabeth Seng, PhD

July 13th 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.